Cefalu et al detail the conclusions and recommendations reached by the American Diabetes Association's Insulin Access and Affordability Working Group in terms of finding solutions to the insulin affordability problem. Throughout 2017, the Working Group assembled existing public information about insulin prices and patient cost-sharing, and convened a series of meetings with stakeholders throughout the insulin supply chain to learn how each entity affects the cost of insulin for the consumer. The Working Group identified increased transparency throughout the insulin supply chain and a number of other interventions as important steps toward developing viable, long-term solutions to improve insulin access and affordability.